dr. nancy l. lewis discusses the correct trial for regorafenib in metastatic colorectal cancer
Published 12 years ago • 578 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:18
dr. nancy l. lewis on resistance among gist patients and regorafenib
-
5:53
redos trial: optimizing regorafenib dosing in metastatic colorectal cancer
-
9:34
regorafenib in colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
1:04
dr. randall holcombe discusses regorafenib for metastatic colorectal cancer
-
3:53
regorafenib in colorectal cancer: optimizing the dose
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
14:07
strategies in metastatic colorectal cancer
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
2:52
metastatic colorectal cancer: trifluridine/tiripacil or regorafenib?
-
1:28
surivival benefit of regorafenib in correct and concur trials
-
1:23
dr. george demetri discusses regorafenib for patients with gist trial results
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
1:47
dr. axel grothey on the time course of regorafenib-associated adverse events
-
7:35
use of regorafenib in refractory mcrc
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
7:46
clinical use of regorafenib in mhcc
-
2:30
second- and third-line therapies in colorectal cancer